Cellular and Molecular Effects of Eribulin in Preclinical Models of Hematologic Neoplasms

Cellular and Molecular Effects of Eribulin in Preclinical Models of Hematologic Neoplasms

Despite the advances in understanding the biology of hematologic neoplasms which has resulted in the approval of new drugs, the therapeutic options are still scarce for relapsed/refractory patients. Eribulin is a unique microtubule inhibitor that is currently being used in the therapy for metastatic...

Full description

Bibliographic Details
Main Authors:	Hugo Passos Vicari, Keli Lima, Leticia Veras Costa-Lotufo, João Agostinho Machado-Neto
Format:	Article
Language:	English
Published:	MDPI AG 2022-12-01
Series:	Cancers
Subjects:	eribulin microtubule dynamics acute leukemias drug resistance
Online Access:	https://www.mdpi.com/2072-6694/14/24/6080

Similar Items

Stathmin dynamics modulate the activity of eribulin in breast cancer cells
by: Mikihiro Yoshie, et al.
Published: (2021-08-01)

Stathmin expression alters the antiproliferative effect of eribulin in leiomyosarcoma cells
by: Mana Azumi, et al.
Published: (2022-12-01)

Activity of Eribulin in a Primary Culture of Well-Differentiated/Dedifferentiated Adipocytic Sarcoma
by: Alessandro De Vita, et al.
Published: (2016-12-01)

Multifarious targets beyond microtubules—role of eribulin in cancer therapy
by: Priya Seshadri, et al.
Published: (2021-12-01)

Eribulin in Cancer Treatment
by: Umang Swami, et al.
Published: (2015-08-01)

Efficacy of Eribulin in Soft Tissue Sarcomas
by: Edward Phillips, et al.
Published: (2022-03-01)

Eribulin and Paclitaxel Differentially Alter Extracellular Vesicles and Their Cargo from Triple-Negative Breast Cancer Cells
by: Petra J. Pederson, et al.
Published: (2021-06-01)

Eribulin drug review
by: Nishitha Shetty, et al.
Published: (2014-01-01)

Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma
by: Sonam Mittal, et al.
Published: (2023-09-01)

Advances in the treatment of soft tissue sarcoma: focus on eribulin
by: Koliou P, et al.
Published: (2018-02-01)

PARP Inhibition Sensitizes Breast Cancer Cells to Eribulin
by: Bahram Sharif-Askari, et al.
Published: (2023-03-01)

Effects of Eribulin on the RNA Content of Extracellular Vesicles Released by Metastatic Breast Cancer Cells
by: Matteo Giulietti, et al.
Published: (2024-03-01)

Eribulin and Confusion: A Previously Unknown Drug Side-Effect
by: Abu Baker Sheikh, et al.
Published: (2020-06-01)

The Microtubule Destabilizer Eribulin Synergizes with STING Agonists to Promote Antitumor Efficacy in Triple-Negative Breast Cancer Models
by: Leila Takahashi-Ruiz, et al.
Published: (2022-12-01)

Efficacy and safety of eribulin in HER2-negative metastatic breast cancer: the results of long-term experience in real clinical practice in Russia
by: Vera A Gorbunova, et al.
Published: (2019-03-01)

Eribulin for the treatment of anthracyclineand taxane-resistant breast cancer: a big step forward towards problem solving
by: E V Artamonova
Published: (2017-09-01)

Eribulin alongwith capecitabine in relapsed carcinoma breast- a retrospective single-Institutional study.
by: Soumita Poddar, et al.
Published: (2023-08-01)

The results of the first retrospective data analysis of eribulin application in patients with metastatic breast cancer in actual clinical practice in Russia
by: L V Bolotina, et al.
Published: (2016-09-01)

Efficacy of Eribulin Plus Gemcitabine Combination in L-Sarcomas
by: María López-Álvarez, et al.
Published: (2022-12-01)

Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer
by: Renaud Sabatier, et al.
Published: (2021-03-01)

The efficacy of the combination of eribulin and trastuzumab in advanced HER2-positive breast cancer: the results of Russian observational study
by: Elena I. Kovalenko, et al.
Published: (2020-05-01)

Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study
by: Sakura Iizumi, et al.
Published: (2017-12-01)

Eribulin-trastuzumab combination in HER2-positive metastatic breast cancer: updated results from a Russian observational study
by: E. I. Kovalenko, et al.
Published: (2021-12-01)

Successfully treatment by eribulin in visceral crisis: a case of lymphangitic carcinomatosis from metastatic breast cancer
by: Jean-David Fumet, et al.
Published: (2018-08-01)

Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer
by: Tsutomu Iwasa, et al.
Published: (2019-10-01)

Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea
by: Tremblay G, et al.
Published: (2016-09-01)

The potential of using eribulin in patients with breast cancer, associated with brain metastasis: the scientific background and the Russian clinical experience
by: Irina V Kolyadina, et al.
Published: (2019-06-01)

Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study
by: Ana López González, et al.
Published: (2022-11-01)

A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK)
by: Min Ho Park, et al.
Published: (2020-12-01)

Eribulin Mesylate Improves Cisplatin-Induced Cytotoxicity of Triple-Negative Breast Cancer by Extracellular Signal-Regulated Kinase 1/2 Activation
by: Hyemi Ko, et al.
Published: (2022-04-01)

Eribulin mesylate exerts antitumor effects via CD103
by: Kazumasa Oya, et al.
Published: (2023-12-01)

Therapeutic efficacy of a four-year treatment with eribulin in a patient with uterine leiomyosarcoma: A case report
by: Motoki Matsuura, et al.
Published: (2023-06-01)

Prediction of survival after eribulin chemotherapy for breast cancer by absolute lymphocyte counts and progression types
by: Tamami Morisaki, et al.
Published: (2021-11-01)

Systematic Analysis of Genetic and Pathway Determinants of Eribulin Sensitivity across 100 Human Cancer Cell Lines from the Cancer Cell Line Encyclopedia (CCLE)
by: Pallavi Sachdev, et al.
Published: (2022-09-01)

Monitoring trends in the absolute lymphocyte count and the neutrophil-to-lymphocyte ratio in patients with breast cancer receiving eribulin
by: Meng-Xia Su, et al.
Published: (2024-02-01)

The role of capecitabine and eribulin in the treatment of metastatic HER2-negative metastatic breast cancer
by: I V Kolyadina, et al.
Published: (2018-09-01)

Combined PI3K Inhibitor and Eribulin Enhances Anti-Tumor Activity in Preclinical Models of Paclitaxel-Resistant, PIK3CA-Mutated Endometrial Cancer
by: Yeong Gyu Jeong, et al.
Published: (2023-10-01)

Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study
by: Nicla La Verde, et al.
Published: (2022-10-01)

Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients?
by: Eijiro Shimada, et al.
Published: (2021-10-01)

Study on the progression types of cancer in patients with breast cancer undergoing eribulin chemotherapy and tumor microenvironment
by: Shinichiro Kashiwagi, et al.
Published: (2018-03-01)